Earnings Call Summary | Artivion(AORT.US) Q2 2024 Earnings Conference
Earnings Call Summary | Artivion(AORT.US) Q2 2024 Earnings Conference
Adjusted EBITDA margin improved by 350 basis points to 19% due to a reduction in general administrative and marketing expenses.The following is a summary of the Artivion, Inc. (AORT) Q2 2024 Earnings Call Transcript:
以下是Artivion公司（AORT）2024年第二季度業績會議通話記錄摘要：
Financial Performance:
金融業績：
Artivion reported Q2 2024 revenue of $98 million, a 10% year-over-year growth in constant currency.
Adjusted EBITDA increased by 35% year-over-year.
Adjusted EBITDA margin improved by 350 basis points to 19% due to a reduction in general administrative and marketing expenses.
Artivion報告2024年第二季度營業收入爲9800萬美元，同比增長10%（按不變匯率計算）。
調整後的EBITDA同比增長35%。
由於一般管理和市場費用的減少，調整後的EBITDA利潤率提高了350個點子，達到19%。
Business Progress:
業務進展：
Artivion expanded its commercial footprint, particularly in Latin America and Asia-Pacific with significant revenue growth.
Product lines On-X, stent grafts, BioGlue, and tissue processing reported strong growth, driven by regulatory approvals and market expansions.
Enhanced focus on innovative products like the NEXUS aortic arch stent graft and proprietary SynerGraft pulmonary valve, positioning them as leaders in the market.
Continued investment in R&D for future products, targeting introduction in new markets like the U.S. and Japan.
Artivion擴大了其商業版圖，特別是在拉丁美洲和亞太地區有着顯著的營業收入增長。
On-X、支架移植、BioGlue和組織處理產品線的強勁增長是由於監管批准和市場擴張推動的。
加強對如NEXUS主動脈弓支架移植術和專有的SynerGraft肺瓣等創新產品的重點關注，將其定位爲市場領導者。
在研發未來產品的同時，繼續投資於針對新市場（如美國和日本）推出的研發項目。
Opportunities:
機會：
Anticipation of strong revenue growth in Latin America and Asia-Pacific regions leveraging industry-leading product portfolio.
NEXUS technology represents a significant global opportunity estimated at $600 million annually upon approval.
Potential U.S. market for AMDS post-approval estimated at $150 million with no competitive alternatives.
藉助業內領先的產品組合，預計在拉丁美洲和亞太地區實現強勁的營收增長。
NEXUS技術代表着每年約6千萬美元的顯著全球機遇，一經批准即可實現。
AMDS發帖獲批後在美國市場的潛在市場規模預計爲1.5億美元，沒有競爭對手。
Risks:
風險：
Projected variability in quarter-to-quarter growth rates for BioGlue due to significant stocking distributor business.
Enrollment pace and potential adoption rate for NEXUS in new regions post-trial.
由於包裝商業的大量庫存生意，BioGlue季度增長率有顯著的變化。
NEXUS在試驗後在新地區的招生速度和潛在採用率。
More details: Artivion IR
更多詳情請查看Artivion IR。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
